These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36998778)

  • 1. Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study.
    Eichau S; López Ruiz R; Ruíz de Arcos M; Ruiz-Peña JL; Navarro G; Calleja MÁ; Moreno-Amador JL; Dotor García-Soto J
    Front Neurol; 2023; 14():1112193. PubMed ID: 36998778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.
    Sandgren S; Novakova L; Nordin A; Axelsson M; Malmeström C; Zetterberg H; Lycke J
    Front Neurol; 2023; 14():1265354. PubMed ID: 37808497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    Rodríguez de Vera Gómez P; Méndez Muros M; Torres Cuadro A; Toyos Sáenz de Miera FJ; López Ruiz R; Guerrero Vázquez R; García González JJ; Garrido Hermosilla AM; Martín Hernández T
    J Neurol; 2024 Jan; 271(1):486-496. PubMed ID: 37773417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
    Zmira O; Halpern AI; Abraham L; Achiron A
    Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
    López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
    Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.
    Kazakou P; Tzanetakos D; Vakrakou AG; Tzartos JS; Evangelopoulos ΜE; Anagnostouli M; Stathopoulos P; Kassi GN; Stefanis L; Kilidireas C; Zapanti E
    Clin Exp Med; 2023 Oct; 23(6):2885-2894. PubMed ID: 36641771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
    J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study.
    Sandgren S; Novakova L; Nordin A; Sabir H; Axelsson M; Malmeström C; Zetterberg H; Lycke J
    Mult Scler Relat Disord; 2024 Nov; 91():105894. PubMed ID: 39293124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
    Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
    Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.
    Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
    J Comp Eff Res; 2023 Jan; 12(1):e220127. PubMed ID: 36440609
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world study of alemtuzumab in a cohort of Italian patients.
    Russo CV; Saccà F; Frau J; Annovazzi P; Signoriello E; Bonavita S; Grasso R; Clerico M; Cordioli C; Laroni A; Capobianco M; Torri Clerici V; Sartori A; Cavalla P; Maniscalco GT; La Gioia S; Caleri F; Giugno A; Iodice R; Carotenuto A; Cocco E; Fenu G; Zaffaroni M; Baroncini D; Lus G; Gallo A; De Mercanti SF; Lapucci C; Di Francescantonio V; Brambilla L; Sormani MP; Signori A
    Eur J Neurol; 2022 Jan; 29(1):257-266. PubMed ID: 34558755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.